VEA
AMRX icon

Virtus ETF Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History

Virtus ETF Advisers’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$637K Buy
36,823
+902
+3% +$12.4K 0.24% 105
2026
Q1 		$446K Hold
35,921
– – 0.21% 124
2025
Q4 		$453K Hold
35,921
– – 0.21% 124
2025
Q3 		$360K Hold
35,921
– – 0.2% 138
2025
Q2 		$291K Hold
35,921
– – 0.18% 150
2025
Q1 		$301K Buy
+35,921
New +$300K 0.2% 152

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Virtus ETF Advisers's AMRX Position: Q2 2026 in Review

Virtus ETF Advisers increased its Amneal Pharmaceuticals (AMRX) stake by 2.5% in Q2 2026, buying an estimated $12.4K and bringing the position to 36,823 shares worth $637K. The position accounts for 0.24% of the portfolio, ranked #105.

Virtus ETF Advisers first reported a position in AMRX in Q1 2025 and has held it in 6 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Virtus ETF Advisers held 36,823 shares of Amneal Pharmaceuticals worth $637K as of Q2 2026.
  • Virtus ETF Advisers bought 902 Amneal Pharmaceuticals shares in Q2 2026, an estimated $12.4K.
  • Amneal Pharmaceuticals made up 0.24% of Virtus ETF Advisers's portfolio in Q2 2026, its #105 holding.
  • Virtus ETF Advisers first reported a position in Amneal Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.